PharmaJet, WHO, Gates Foundation in Somalia polio vaccination campaign

PharmaJet Logo

Closely-held PharmaJet’s Tropis intradermal needle-free injection system is being used in a campaign in Somalia, delivering inactivated polio vaccine to more than 110,000 children.

The purpose of the campaign, funded in part by the Bill and Melinda Gates Foundation, using PharmaJet’s needle-free delivery product supplied by the WHO, is to ensure children under five years of age receive their full regimen of inactivated polio vaccine. A second dose will be given with the PharmaJet Topis device after one month. 

The PharmaJet needle-free system was chosen for the Somalia campaign because the published data demonstrated improved coverage and user preferences. In addition, fractional dose delivery by Tropis, provides a cost-saving alternative to traditional delivery methods and can extend limited stocks. 

PharmaJet experts provided a training education seminar in Mogadishu in early September to build a pool of competent instructors from the Somalia Ministry of Health, WHO and UNICEF, who then trained regional healthcare leaders throughout the campaign regions. 

In a statement, Chris Cappello, president and CEO of PharmaJet, said “mean vaccine coverage [has shown] a nearly 20% increase over previous campaigns when using the PharmaJet system.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.